All In Biotech

Drug Trial Radar · NCT07491146

Phase II Clinical Study of the Efficacy and Safety of HSK55718 in the Treatment of Abdominal Postoperative Pain

To Evaluate the Efficacy and Safety of HSK55718 for Injection in Patients With Abdominal Postoperative Pain: a Multicenter, Randomized, Double-blind, Placebo/Positive Control Phase II Clinical Trial.

Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

May 23, 2026

Primary completion

Oct 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
Yingyong Zhou,MD,PhDAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, placebo-controlled, and positive-controlled phase II clinical trial was conducted to evaluate the efficacy and safety of HSK55718 injection for postoperative analgesia in patients undergoing abdominal surgery. The primary objective was to evaluate the efficacy of HSK55718 for postoperative analgesia after abdominal surgery. The secondary objective was to evaluate the safety and pharmacokinetic profile of TRD303 solution for postoperative analgesia after abdominal surgery.

Conditions

  • Pain After Abdominal Surgery

Interventions

  • Low dose HSK55718Drug

    NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, the first dose of HSK55718 injection 15mg was given intravenously, and then 7.5mg HSK55718 injection or normal saline was given intermittently every 6 hours

  • Medium Dose HSK55718Drug

    NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, the first dose of HSK55718 injection 60mg was given intravenously, and then 30mg HSK55718 injection or normal saline was given intermittently every 6 hours.

  • High dose HSK55718Drug

    NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, the first dose of HSK55718 injection 120mg was given intravenously, and then 60mg HSK55718 injection or normal saline was given intermittently every 6 hours

  • MorphineDrug

    NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, morphine injection 2mg was given intravenously as the first dose, and then morphine injection 2mg was given intermittently every 6 hours

  • Normal saline solutionDrug

    NRS pain score was performed immediately after emergence from anesthesia. After the postoperative NRS pain score ≥4, normal saline solution was given intravenously as the first dose, and then normal saline solution was given intermittently every 6 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The time-weighted summed pain intensity differences over 24 h (SPID0-24 h) at restTime frame: From administration until 24 hours after administration

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Third Xiangya Hospital of Central South University, Changsha, hunan

    Changsha, Hunan, China · Recruiting

  • Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.